ARIAD Pharmaceuticals: Timothy P. Clackson president of R&D
Dr. Clackson, who joined ARIAD in 1994, also retains his position as Chief Scientific Officer.
Dr. Clackson has nearly twenty years of experience in the biopharmaceutical industry. He served as ARIAD's Senior Vice President and Chief Scientific Officer since September 2003 and previously held a number of scientific positions, starting as a research scientist and rising through the management ranks over the past fifteen years.
Prior to joining ARIAD, Dr. Clackson was a postdoctoral fellow at Genentech, Inc., where he studied the molecular basis for human growth hormone function. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford.
Dr. Clackson received his Ph.D. degree in Biology from the University of Cambridge, for research conducted at the MRC Laboratory of Molecular Biology into antibody engineering and the development of phage-display technology. The company also announced three important additional promotions and new positions.
Frank G. Haluska, M.D., Ph.D. has been named Vice President, Clinical Research and Development and Chief Medical Officer, reporting to Dr. Clackson.
Dr. Haluska has been with ARIAD for nearly three years and has led ARIAD's clinical affairs group. He has contributed to all of the company's medical programs, including leadership of the ongoing clinical trial of ARIAD's investigational pan-BCR-ABL inhibitor, AP24534.
Prior to joining ARIAD, Dr. Haluska held senior academic positions at Harvard Medical School, Massachusetts General Hospital and the Dana-Farber Cancer Institute. He will oversee the pivotal trial of AP24534 in patients with resistant and refractory chronic myeloid leukemia, which is scheduled to begin patient enrollment in the second half of this year.
Edward M. Fitzgerald has been promoted to Executive Vice President and Chief Financial Officer, reporting to Dr. Berger. Mr. Fitzgerald has been with ARIAD for more than eight years and has led the business and finance functions of the Company. His new role will include oversight of ARIAD's commercial operations.
Pierre F. Dodion, M.D., M.B.A. will move into the newly created position of Senior Vice President, Corporate Development
Dr. Dodion has been with ARIAD for more than three years, most recently heading clinical development and medical affairs, and he will now be responsible for leading business development and corporate strategy for ARIAD. ■
LATEST MOVES FROM Massachusetts
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
- Acer Therapeutics appoints William T. Andrews as CMO
More inside POST
The most important 'no' in your career Leadership